Loading clinical trials...
Loading clinical trials...
Randomized, Open-label, Multicenter Study of Icotinib as Adjuvant Therapy in Treating Stage II-IIIA Non-small-cell Lung Cancer Patients With Positive EGFR Mutation
Conditions
Interventions
1-year treatment with icotinib
2-year treatment with icotinib
Locations
1
China
Beijing Cancer hospital
Beijing, China
Start Date
August 1, 2013
Primary Completion Date
December 1, 2015
Completion Date
August 1, 2017
Last Updated
May 22, 2015
NCT07336732
NCT05568212
NCT06574347
NCT02448992
NCT06281964
NCT05904379
Lead Sponsor
Betta Pharmaceuticals Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions